TGFBI rs121909211: Understanding Corneal Dystrophy Associations
The rs121909211 variant is a rare genetic change located within the TGFBI gene. It is clinically associated with specific inherited corneal dystrophies, which are conditions that cause protein deposits to accumulate in the eye.
What each genotype means
Typical TGFBI profile
This genotype represents the common, non-pathogenic sequence for this position in the TGFBI gene. Individuals with this genotype do not carry the specific R124H mutation associated with certain inherited corneal dystrophies.
This is the most common genotype found in the general population.
Increased risk of corneal dystrophy
This genotype indicates the presence of one copy of the R124H mutation (also known as c.371G>A). This variant is associated with Granular Corneal Dystrophy Type 2, also known as Avellino corneal dystrophy, which involves the accumulation of protein deposits in the cornea. You should discuss these findings with an ophthalmologist or a genetic counselor to understand potential ocular health implications.
This variant is rare in the general population, though it has been identified at an allele frequency of approximately 0.10% in some large population studies.
High risk of corneal dystrophy
This genotype indicates the presence of two copies of the R124H mutation. This is strongly associated with the development of inherited corneal dystrophies, which may lead to progressive vision changes due to structural protein deposits in the eye. It is recommended to consult with an eye specialist for regular monitoring and to discuss clinical management options.
This homozygous genotype is extremely rare in the general population.
What is the rs121909211 Variant?
The rs121909211 variant is a single nucleotide polymorphism (SNP) located on chromosome 5. In genetic databases, it is often identified by the specific amino acid change it causes in the resulting protein, known as p.Arg124Leu. This variant represents a structural change in the DNA sequence of the TGFBI gene. Because it alters the genetic code, it can lead to the production of a modified version of the TGFBI protein. This variant is classified as pathogenic in clinical databases, meaning it has a well-documented association with specific health conditions. It is important to note that this variant is rare in the general population, and its presence does not automatically guarantee the development of a clinical condition, as genetic expression can be complex and influenced by other factors.
The Role of the TGFBI Gene
The TGFBI gene provides the instructions for creating the transforming growth factor beta-induced protein. This protein is secreted by cells and becomes a vital component of the extracellular matrix, the structural network that supports tissues throughout the body. In the eye, this protein is particularly important for the health and maintenance of the cornea, the clear outer layer that covers the front of the eye. The TGFBI protein assists in cell adhesion, which helps cells stick to one another and move correctly during tissue development and repair. When the TGFBI gene contains certain mutations, the resulting protein may not fold or function correctly. This can lead to the accumulation of abnormal protein deposits within the corneal layers, which may eventually cloud the cornea and affect vision.
Research and Clinical Associations
Scientific research has strongly linked the rs121909211 variant to specific inherited eye conditions, most notably Reis-Bucklers corneal dystrophy and Avellino corneal dystrophy. These conditions are characterized by the buildup of abnormal protein deposits in the corneal stroma or Bowman's layer. The evidence for this association is considered robust, as the variant is frequently identified in individuals presenting with these specific clinical phenotypes. Current research is actively exploring how these deposits form and investigating potential therapeutic interventions, such as the use of small interfering RNA (siRNA) to silence the expression of the mutant allele. While the link between this variant and corneal dystrophy is well-established in clinical literature, the severity and age of onset can vary between individuals, suggesting that other genetic or environmental factors may also play a role in how the condition manifests.
Population Frequency and Interpretation
The rs121909211 variant is classified as rare across global populations. Because it is not a common polymorphism, it is not typically found in the general population at high frequencies. For individuals who receive a report identifying this variant, it is essential to understand that this information is for educational purposes only. Genetic testing results should always be interpreted by a qualified healthcare professional, such as a genetic counselor or an ophthalmologist who specializes in corneal diseases. A positive result for a rare pathogenic variant does not constitute a medical diagnosis. If you have concerns about your vision or a family history of corneal conditions, you should discuss these findings with your clinician to determine if further clinical evaluation or monitoring is appropriate for your specific situation.
How common is this variant?
The rs121909211 variant is considered rare in the general population, with its frequency varying significantly depending on the specific ancestral background and clinical cohort studied.
Frequently asked questions
What is TGFBI-related corneal dystrophy?
TGFBI-related corneal dystrophy is a group of inherited eye conditions caused by mutations in the TGFBI gene. These mutations lead to the accumulation of abnormal protein deposits in the cornea, which can cause clouding and vision impairment.
Is rs121909211 the same as the R124L mutation?
Yes, rs121909211 is the SNP identifier for the genetic change that results in the p.Arg124Leu (R124L) amino acid substitution in the TGFBI protein. Both terms refer to the same underlying genetic variant.
Can I prevent corneal dystrophy if I have this variant?
Currently, there is no known way to prevent the development of corneal dystrophy if you carry a pathogenic variant. You should consult with an ophthalmologist to discuss regular eye exams and monitoring for any signs of the condition.
Are there treatments for TGFBI corneal dystrophies?
Treatment options depend on the severity of the symptoms and may include corneal transplantation or laser surgery to remove deposits. Research into gene-silencing therapies, such as siRNA, is ongoing but is not yet a standard clinical treatment.
Sources & further reading
Educational information only, last refreshed 9/19/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121909211?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29